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The overall aim of this thesis was to determine epigenetic changes in peripheral immune cells 
from Multiple Sclerosis (MS) patients. MS is a chronic inflammatory neurodegenerative 
disease, which initially presents itself during young adulthood. Big consortia have identified 
over 230 different polymorphisms contributing to the risk of developing disease, with many 
of these polymorphisms located in immune genes. However, the odds ratios of these 
polymorphisms are small and many known environmental risk factors are contributing to the 
disease. This indicates that the risk may partially be conferred through epigenetic changes 
such as DNA methylation.  
In this thesis, we investigate the role of DNA methylation in different peripheral immune 
cells using genome-wide DNA methylation arrays. We first characterized DNA methylation 
patterns in four different immune cell types form relapsing-remitting (RRMS), secondary-
progressive (SPMS) patients and healthy controls (HC) and compared them with each other. 
Here we found a shared signature between all cells types, and in SPMS we found a specific 
neurodegenerative signal, while in MS patients, we saw lymphocyte signaling and T cell 
activation being affected. The top changes in CD4+ T cells indicate a change in 
the VMP1/MIR21 locus. We functionally investigated this and found lower miR-21 
expression and an increase of miR-21 target genes. Because the most numerous methylation 
changes were found in CD19+ B cells, we further investigated CD19+ cells in a second larger 
cohort. After meta-analysis, the changes in B cells indicate differences in metabolism and 
activation between RRMS and HC. To analyze the shared pathway data, we developed a 
method to cluster pathways, which we further developed into an R package called 
GeneSetCluster. 
We investigated the effects of dimethyl fumarate (DMF) and rituximab treatment on DNA 
methylation in CD4+ and CD14+ cells. The different treatments had a different cell type 
specific signature as well as different kinetics. After DMF treatment, we found changes in 
reactive oxygen species (ROS) signaling and T cell subtype associated genes. Furthermore, 
we identified a polymorphism associated with treatment outcome and ROS production that 
does not associate with disease susceptibility. After rituximab treatment, we found 
differences in activation, metabolism and motility associated genes.  
Our findings collectively underline the importance of investigating epigenetic changes in 
multiple cell types to identify novel, potentially modifiable, mechanisms involved in the 
etiology and pathogenesis of complex diseases like MS. 
  
LIST OF SCIENTIFIC PAPERS 
I. Combining evidence from four immune cell types identifies DNA methylation 
patterns that implicate functionally distinct pathways during Multiple 
Sclerosis progression.  
 
Ewing E, Kular L, Fernandes SJ, Karathanasis N, Lagani V, Ruhrmann S, 
Tsamardinos I, Tegner J, Piehl F, Gomez-Cabrero D, Jagodic M.  
 
EBioMedicine. 2019 May;43:411-423.  
: 10.1016/j.ebiom.2019.04.042. Epub 2019 Apr 30. PMID: 31053557. 
 
II. Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-
remitting multiple sclerosis associates with lower miRNA-21 levels and 
concomitant up-regulation of its target genes. 
 
Ruhrmann S, Ewing E, Piket E, Kular L, Cetrulo Lorenzi JC, Fernandes SJ, 
Morikawa H, Aeinehband S, Sayols-Baixeras S, Aslibekyan S, Absher DM, Arnett 
DK, Tegner J, Gomez-Cabrero D, Piehl F, Jagodic M.  
 
Mult Scler. 2018 Sep;24(10):1288-1300. doi: 10.1177/1352458517721356. Epub 
2017 Aug 2.. PMID: 28766461 
 
III. GeneSetCluster: a tool for summarizing and integrating gene-set analysis 
results. 




IV. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple 
sclerosis associates with ROS pathway in monocytes. 
 
Carlström KE, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson SL, 
Checa A, Badam TVS, Huang J, Gomez-Cabrero D, Gustafsson M, Al Nimer F, 
Wheelock CE, Kockum I, Olsson T, Jagodic M, Piehl F.  
 
Nat Commun. 2019 Jul 12;10(1):3081. doi: 10.1038/s41467-019-11139-3., PMID: 
3130067 
 
V. Investigating a role of B cells and their depletion in relapsing-remitting 
Multiple Sclerosis using DNA methylation patterns 
 
Ewing E, Al Nimer F, Kular L, Stridh P, Olsson T, Khademi M, Gomez-Cabrero 







LIST OF ADDITIONAL PUBLICATIONS 
I. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation 
phenotype prior to the onset of rheumatoid arthritis. 
 
Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, Huizinga 
TW, Wuhrer M, van Schaardenburg D, Toes RE, Scherer HU. 
 
Ann Rheum Dis. 2015 Jan;74(1):234-41. doi: 10.1136/annrheumdis-2013-203565. Epub 2013 
Oct 8. PMID: 24106048 
 
II. Clinical validation study of genetic markers for capecitabine efficacy in metastatic 
colorectal cancer patients. 
 
van Huis-Tanja LH, Ewing E, van der Straaten RJ, Swen JJ, Baak-Pablo RF, Punt CJ, 
Gelderblom AJ, Guchelaar HJ. 
 
Pharmacogenet Genomics. 2015 Jun;25(6):279-88. doi: 10.1097/FPC.0000000000000119. 
PMID: 25815774 
 
III. Epigenetic research in multiple sclerosis: progress, challenges, and opportunities. 
 
Zheleznyakova GY, Piket E, Marabita F, Pahlevan Kakhki M, Ewing E, Ruhrmann S, 
Needhamsen M, Jagodic M, Kular L. 
 
Physiol Genomics. 2017 Sep 1;49(9):447-461. doi: 10.1152/physiolgenomics.00060.2017. 
Epub 2017 Jul 28. Review. PMID: 28754822 
 
IV. Usability of human Infinium MethylationEPIC BeadChip for mouse DNA methylation 
studies. 
 
Needhamsen M, Ewing E, Lund H, Gomez-Cabrero D, Harris RA, Kular L, Jagodic M. 
 
BMC Bioinformatics. 2017 Nov 15;18(1):486. doi: 10.1186/s12859-017-1870-y. PMID: 
29141580 
 
V. Fatal demyelinating disease is induced by monocyte-derived macrophages in the 
absence of TGF-β signaling. 
 
Lund H, Pieber M, Parsa R, Grommisch D, Ewing E, Kular L, Han J, Zhu K, Nijssen J, 
Hedlund E, Needhamsen M, Ruhrmann S, Guerreiro-Cacais AO, Berglund R, Forteza MJ, 
Ketelhuth DFJ, Butovsky O, Jagodic M, Zhang XM, Harris RA. 
 




VI. DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in 
multiple sclerosis. 
 
Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, 
Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, 
Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, 
Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, 
Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, 
Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, 
Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M. 
 
Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5. PMID: 29921915 
 
VII. Competitive repopulation of an empty microglial niche yields functionally distinct 
subsets of microglia-like cells. 
 
Lund H, Pieber M, Parsa R, Han J, Grommisch D, Ewing E, Kular L, Needhamsen M, 
Espinosa A, Nilsson E, Överby AK, Butovsky O, Jagodic M, Zhang XM, Harris RA. 
 
Nat Commun. 2018 Nov 19;9(1):4845. doi: 10.1038/s41467-018-07295-7. PMID: 30451869 
 
VIII. Epigenetic Alterations Associated With Early Prenatal Dexamethasone Treatment. 
 
Karlsson L, Barbaro M, Ewing E, Gomez-Cabrero D, Lajic S 
 
J Endocr Soc. 2018 Dec 12;3(1):250-263. doi: 10.1210/js.2018-00377. eCollection 2019 Jan 
1. PMID: 30623163 
 
 
IX. Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple 
sclerosis. 
 
Kular L, Needhamsen M, Adzemovic MZ, Kramarova T, Gomez-Cabrero D, Ewing E, Piket 
E, Tegnér J, Beck S, Piehl F, Brundin L, Jagodic M. 
 
Clin Epigenetics. 2019 May 30;11(1):86. doi: 10.1186/s13148-019-0678-1. PMID: 31146783 
 
X. Non-parametric combination analysis of multiple data types enables detection of novel 
regulatory mechanisms in T cells of multiple sclerosis patients. 
 
Fernandes SJ, Morikawa H, Ewing E, Ruhrmann S, Joshi RN, Lagani V, Karathanasis N, 
Khademi M, Planell N, Schmidt A, Tsamardinos I, Olsson T, Piehl F, Kockum I, Jagodic M, 
Tegnér J, Gomez-Cabrero D. 
 





1 Multiple Sclerosis ............................................................................................................ 9 
1.1 Disease and symptoms .......................................................................................... 9 
2 Epidemiology ................................................................................................................ 10 
2.1 Genetics ............................................................................................................... 10 
2.2 Environmental Factors ........................................................................................ 11 
3 The role of immune cells in MS pathology .................................................................. 11 
3.1 Role of T cells ...................................................................................................... 11 
3.2 Role of B cells ..................................................................................................... 12 
3.3 Role of monocytes/macrophages ........................................................................ 12 
4 Treatment ....................................................................................................................... 13 
5 Epigenetics ..................................................................................................................... 13 
5.1 DNA methylation ................................................................................................ 13 
5.2 Epigenetic Methods ............................................................................................. 15 
5.3 analysis pipelines ................................................................................................. 15 
6 Epigenetic studies in MS ............................................................................................... 17 
6.1 Immune cell studies ............................................................................................. 17 
6.2 Epigenetic interaction with environment ............................................................ 19 
6.3 CNS studies ......................................................................................................... 21 
6.4 Other epigenetic regulation ................................................................................. 22 
7 Challenges ..................................................................................................................... 23 
7.1 Comparing among studies ................................................................................... 23 
7.2 Integrating studies ............................................................................................... 23 
7.3 Meta-analysis over paired data Omics data ........................................................ 23 
7.4 Functional relevance ............................................................................................ 24 
8 Thesis aims .................................................................................................................... 27 
9 Results ............................................................................................................................ 28 
9.1 Study I .................................................................................................................. 28 
9.2 Study II ................................................................................................................ 29 
9.3 Study III ............................................................................................................... 30 
9.4 Study IV ............................................................................................................... 30 
9.5 Study V ................................................................................................................ 32 
10 Conclusions and future perspectives............................................................................. 34 
11 Acknowledgements ....................................................................................................... 37 
12 References ..................................................................................................................... 39 
 
  
LIST OF ABBREVIATIONS 
MS Multiple Sclerosis 
CNS Central nervous system 
BBB Blood brain barrier 
EDSS Expanded disability status scale 
MRI Magnetic resonance imaging 
RRMS Relapsing-remitting multiple sclerosis 
CIS Clinically isolated syndrome 
SPMS Secondary progressive multiple sclerosis 
PPMS Primary progressive multiple sclerosis 
MZ Monozygotic twins 
HLA Human leukocyte antigen 
SNPs Single nucleotide polymorphisms 
APC Antigen presenting cells 
BMI Body mass index 
EBV Eppstein-Barr virus 
Tregs Regulatory T helper cell 
TCR T cell receptor 
EAE Experimental autoimmune encephalomyelitis 
MOG Myelin oligodendrocyte glycoprotein 
MAIT Mucosal-assocaited invariant T cells 
CSF Cerebral spinal fluid 
BAFF B cell activating factor 
DMF Dimethyl fumarate 
ROS Reactive oxygen species 
HDACs Histone deacetylase 
5mC 5-methylcytosine 
DNMT DNA methyltransferases 
TET Ten-eleven translocation 
5hmC 5-hydroxymethylcytosine 
DMP Differentially methylated positions 
 
 
DMR Differentially methylated region 
450K Infinium Human Methylation 450K BeadChip 
EPIC Infinium Human Methylation EPIC BeadChip 
WGBS Whole genome bisulfite sequencing 
RRBS Reduced representation bisulfite sequencing 
MBD-seq Methyl-CpG binding domain sequencing 
meDIP-seq Methyl-CpG sequencing 
β Beta respresenting the ratio C / T 
BMIQ Beta-mixture in quantile normalization 
PBMC Peripheral blood mononuclear cells 
PCA Principal component analysis 
LT-α Lymphotoxin-alpha 
TSS Transcription start site 
IFN Interferon 
NRF2 Nuclear factor erythoid 2-related factor 2 
VDR Vitamin D receptor 
LCL Lymphoblastoid cell lines 
NAWM Normal appearing white matter 
HATs Histone acetyltransferase 
lncRNA Long non-coding RNA 
sncRNA Small non-coding RNA 
miRNA mircoRNAs 
Ago Argonaute 
KS Kolmogorov-smirnov test 
IPA Ingenuity pathway analysis 
HC Healthy controls 




1 MULTIPLE SCLEROSIS 
1.1 DISEASE AND SYMPTOMS 
Multiple Sclerosis (MS) is a chronic inflammatory disease, it is located in the central nervous 
system (CNS), and MS is defined by the autoimmune destruction of myelin, which results in 
the loss of neurons (1, 2). It is the second most common debilitating disease in young adults, 
and it affects around 2.5 million people worldwide. Patients are usually diagnosed between 
20-40 years of age, with women being affected nearly three times as often as men (3). The 
disease is characterized by an immune response against myelin, which is a lipid-rich layer 
produced by oligodendrocytes. Myelin insulates axons to allow for fast transmission of 
electrical impulses within the nervous system as well as providing metabolic support for the 
axons. This immune response causes the breakdown of the blood brain barrier (BBB), 
infiltration of immune cells into the CNS and subsequent development of inflammatory and 
demyelinating lesions in both brain and spinal cord (4). Later in the disease course, there is 
notable neurodegeneration and severe brain atrophy, tough brain atrophy can be observed in 
the initial stages also. 
MS symptoms can vary greatly depending on the localization of the lesions in the CNS and 
can include changes in sensation, muscle weakness, muscle spasms, difficulties with 
coordination and balance, problems in speech, visual problems, fatigue and acute or chronic 
pain syndromes, bladder and bowel difficulties, cognitive impairment, or depression. The 
patient disability is measured using the Expanded Disability Status Scale (EDSS) (5). Using 
modern magnetic resonance imaging (MRI) we can detect these lesions in the brain (Fig. 1), 
these are classified either with different time pulses or with contrast enhancing agents.  
Lesions detected using longer pulses are classified as T2 lesions, and three or more new T2 
lesions in a 2 year period predicts unfavorable for patient outcome (6). The most commonly 
used contrast-enhancing agent in MS is Gadolinium-based, which normally is unable to pass 
through the BBB unless there is an active or chronic lesion in the brain (7). 
The initial diagnosis of most MS patients (~85-90%) is the relapsing-remitting form of MS 
(RRMS). However, there is a preclinical phase where the disease is ongoing but does not 
present itself with symptoms yet (8). The initial clinical event is called a clinically isolated 
syndrome (CIS), but after the second relapse, patients are diagnosed with RRMS (Fig.1). The 
RRMS form of the disease presents itself with recurring episodes of acute neurological 
symptoms (relapses) followed by recovery (remission). While inflammation is present in all 
stages of MS, it is more pronounced in RRMS than in the progressive phase. The RRMS 
stage is currently quite successfully treated with several disease-modifying therapies, 
described below, which broadly target the immune system and treatments are sometimes 
accompanied by severe adverse effects (9). However, after roughly 15-20 years (10, 11)the 
majority of RRMS patients convert to a more progressive form of MS called secondary-
progressive MS (SPMS). SPMS is noted for the accumulation of axonal damage, neuronal 
loss and the persistent increase in neurological disability. The remainder of the patients exert 
a different disease course, called primary-progressive MS (PPMS), which presents itself with 
a more severe disease course from onset without the complete or partial recovery phase and 
displays less inflammation while still causing a lot of nerve damage. Recently the first drugs 
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became available for disease stages other than RRMS, recently ocrelizumab was approved 
for PPMS and siponimod was approved for SPMS patients.  
 
 
Figure 1. Multiple Sclerosis (MS) disease course. This figure displays the disease course of the 
average MS patient starting with relapsing-remitting phase and later on progressing to the secondary 
progressive phase of the disease. A relative contribution of inflammatory and neurodegenerative 




While the exact cause of MS remain unknown, current epidemiological data establish MS as 
a complex disease with a strong genetic and environmental component. Family members of 
MS patients have a higher chance of developing MS, with monozygotic twins (MZ) 
displaying a concordance rate of ~15-25% compared to 2-5% in dizygotic twins, indicating 
the importance of genetic as well as environmental factors (12, 13). The first discovered and 
still the strongest genetic risk factor lies within the Human Leukocyte Antigen (HLA) 
locus(14), specifically a class II allele of the HLA-DRB1 gene, HLA-DRB1*15:01. Large 
international consortia (15, 16) conducted genome-wide association studies and custom-
designed arrays, which have identified over 230 non-HLA single nucleotide polymorphisms 
(SNPs) which predispose for MS. Many of these lie in genes associated with T-cell related 
signaling pathways, as well as multiple variants and alleles of the HLA locus itself (17). The 
class II HLA molecules are expressed on antigen presenting cells (APCs) and present peptide 
antigens to CD4+ T cells, thus playing a crucial role in the antigen-specific immune response.  
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2.2 ENVIRONMENTAL FACTORS 
In MS, the relatively low concordance rate in MZ twins indicates a possible role for the 
stochastic nature of the adaptive immune system regarding molecular mimicry, but also the 
environmental exposure as crucial to disease development. Epidemiological studies have 
identified environment risk factors such as lack of vitamin D/sun exposure, smoking, elevated 
Body Mass Index (BMI) in early life and Epstein-Barr virus (EBV) infection (18). 
Interestingly, many of these environmental cues seem to act during a susceptible window 
encompassing childhood and adolescence (4, 19). This has been observed in migration 
studies, where a reduced risk in migrants moving from a high- to a low-risk area was seen if 
they moved during the first two decades of life (19). Conversely, the migration from a low- 
to a high-risk area did not alter the risk of MS in the migrants, however, the increased risk 
was seen in their children. Even though these environmental risk factors are well studied in 
their association with MS, other environmental factors such as the gut microbiome, including 
the brain-gut axis are attracting more attention recently (20, 21). Furthermore melatonin 
levels (22) also appear to influence MS disease.  
 
3 THE ROLE OF IMMUNE CELLS IN MS PATHOLOGY 
The autoimmune response in MS is a result of the interaction of many cell types. Although 
multiple immune cells have been implicated in the immunopathology of MS, this thesis focuses 
on T and B cells and monocytes, and thus their role in MS is briefly described in the following 
sections. 
3.1 ROLE OF T CELLS 
The CD4+ T cells, also known as T helper cells, help regulate or suppress immune cells by 
releasing cytokines, which assist in activating cytotoxic T cells, B cell antibody class switching 
and macrophages. In MS, relevant subtypes are the pro-inflammatory Th1 and Th17 cells and 
the repressive regulatory T cells (Tregs). Activation of CD4+ T cells occurs by binding of the 
T cell receptor (TCR) that recognizes a peptide antigen presented by the HLA molecule on a 
professional APCs, though a second and third activation signals are needed as well. The CD4+ 
cells then express cytokines such as IFNγ and IL17A, which in turn create a positive feedback 
loop leading to the activation of more CD4+ T cells. MS is associated with an unbalanced ratio 
of Tregs vs Th1 and Th17 (23). In addition, Tregs function has also been shown to be impaired 
in MS (24, 25). Tregs play a critical role in maintaining peripheral immune tolerance by 
suppressing autoimmune responses. Interesting is that in the MS GWAS several Treg related 
genes were found including IL-2 signaling, CD25, and CD127 (26). CD4+ T cells help in 
disrupting the BBB and the production of cytokines attracting monocytes and neutrophils, 
together which form MS lesions (27). The role of CD4+ T cells in MS is well established in 
part due to the animal model of M-like disease experimental autoimmune encephalomyelitis 
(EAE), where transfer of activated myelin oligodendrocyte glycoprotein (MOG)-specific CD4+ 
T cells is enough to cause demyelinating disease (28). 
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CD8+ T cells are much more predominant in active MS lesions than CD4+ T cells, and they are 
the primary cytotoxic effector cells that drive myelin destruction. Measuring TCR variability 
in brain lesions indicate a limited range of TCRs, the cause for this could be local T cell 
expansion at the site of inflammation (29). Higher frequencies of CD8+ T cells correlate with 
axonal damage (30). In MS lesions, 25% of the CD8+ fraction produce IL17, a characteristic 
of mucosal-associated invariant T (MAIT) cells (31), MAIT cells are reported to be important 
for regulating Th1 responses and the number of MAIT cells is reduced in the peripheral blood 
of MS patients, indicating that these cells might have several anti-inflammatory properties (32).  
3.2 ROLE OF B CELLS 
B cells have been getting more interest in the immunopathology of MS over the last few years. 
B cells have many functions, these include antibody production, where differentiated B cells 
undergo affinity maturation and start to produce antigen-binding proteins. B cells are also 
APCs, and have roles in antigen presentation, where soluble autoantigens bound on the B cell 
surface are presented to T cells. Part of this APC function is autoantigen transport, where B 
cells capture specific antigens and transport them to the lymph nodes. Finally, B cells also 
produce several pro and anti-inflammatory cytokines (33). In some autoimmune diseases, B 
cells generate pathogenic autoantibodies, however, there is no conclusive evidence of such 
autoantibodies playing a pathogenic role in MS (34), and antibodies alone are also not capable 
of inducing EAE, indicating that in MS the role of B cells is related to cytokine production and 
APC function. Despite this, the IgG oligoclonal bands in the cerebral spinal fluid (CSF) of MS 
patient are a useful clinical biomarker for MS diagnosis (35). CXCR13, a chemokine specific 
for B cells is found in the CSF, and has a positive correlation with relapse rate (36). 
Similar to T cells, there are many subtypes of B cells, with the memory B cells gaining 
increasing evidence in the context of MS. These are long-lived B cells, which remain after the 
initial inflammation, and that can evoke an enhanced response to reinfection, particularly in 
response to viruses (37). Only treatment with drugs which target memory B cells appear to be 
beneficial in MS. Tabalumab, which inhibits B cell activating factor (BAFF), depletes mature, 
but not memory B cells, and has no clinical effect in MS (38). Meanwhile, rituximab treatment 
is a highly successful MS drug and depletes both mature B cells and memory B cells (39). The 
number of memory B cells in the blood of MS patients has also been reported to be reduced 
after dimethyl fumarate (DMF) treatment (40) and fingolimod treatment results in a reduction 
of memory B cell migration into the CNS (41), where the memory B cells are the most 
numerous B cells (42). Furthermore, it is in the CNS where the EBV transformed B memory 
cells reside (43). Memory B cells are also reported to activate brain-homing autoreactive CD4+ 
T cells (44), via interacting with HLA-DR on the CD4+ T cell surface.  
3.3 ROLE OF MONOCYTES/MACROPHAGES 
Monocytes and macrophages are both APCs and part of the innate immune system, and their 
main functions are phagocytosis, antigen presentation and cytokine production. T cells recruit 
monocytes and macrophages to the CNS following BBB disruption. Preventing the 
accumulation of macrophages delays the initiation of EAE and results in a less severe disease 
course (45). Their contribution to MS could be due to the production of reactive oxygen species 
(ROS), which are potent immune regulators. With the different ROS being integral to many 
 
 13 
processes in the immune system, including T cell activation, proliferation and apoptosis (46). 
DMF has been reported to dampen the monocyte response by altering its ROS production (47). 
Furthermore, active lesions are characterized by myelin-filled macrophages, which 
phagocytose myelin debris following T cell mediated destruction (48).  
 
4 TREATMENT 
Currently several treatment options exist for patients with RRMS, some are broadly targeting 
drugs such as interferons, others are more specific, such as natalizumab, which stops 
lymphocytes from passing the BBB by which it prevents CNS inflammation (49). Fingolimod 
(50) and siponimod (51) both target the sphingosine-1-phosphate receptor to trap 
lymphocytes in the lymph nodes, preventing their contribution to the autoimmune response, 
fingolimod also inhibits histone deacetylases (HDACs) in the brain. Glatiramer acetate is a 
mixture of several synthetic polypeptides that are believed to inhibit the binding of myelin 
proteins to HLA (52). DMF has several effects, though the exact beneficial means are 
unknown but seems to be involved in modulation of ROS signaling, which is essential in 
BBB, macrophage and monocyte functioning (53). Rituximab, ocrelizumab, ublituximab and 
ofatumumab are monoclonal antibodies against B cell marker CD20 (54). B cell depletion 
with anti-CD20 leaves the antibody-producing plasma cells remain unaffected, highlighting 
the importance of the antigen presenting role and cytokine production of the B cells as 
possible drivers of MS. B cell depletion seems to work by modulating T cell responses, 
reducing inflammatory cytokines and depleting the EBV reservoir (55). Despite the 
numerous available treatments for RRMS, most patients end up switching from first line 
treatment to a second or later choice, indicating that proper selection of initial treatment is 
difficult due to heterogonous nature of MS (56). 
 
5 EPIGENETICS 
The British embryologist C.H. Waddington coined the term epigenetics in 1942 as pertaining 
to epigenesis or the epigenotype (57). Currently, it is defined as the study of heritable changes 
in gene function that do not involve changes in DNA sequence. This means it covers 
mechanisms that make up the phenotypical state of a cell despite the same genetic background 
(Fig. 2A). The best known epigenetic mechanisms include DNA methylation, histone 
modifications and non-coding RNAs. Dysregulation of these regulators at any level can 
influence disease risk and severity. Despite over 230 SNPs currently known to affect MS risk, 
the odds ratio of these SNPs is small, indicating that there is a role for environmental risk 
factors. As epigenetics lies at the molecular interface between the genetic background and 
environmental exposure, it might provide further insights into MS risks and pathogenesis. 
5.1 DNA METHYLATION 
DNA methylation is the covalent addition of a methyl group to the 5th carbon of cytosine, 
known as 5-methylcytosine (5mC), and is usually occurs in a CpG dinucleotide context (Fig. 
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2B). CpG indicates that it is a cytosine followed by a phosphate followed by guanine that is 
methylated. Non-CpG methylation also occurs but is restricted to specific cell types such a 
pluripotent stem cells and CNS resident cells (58). A single CpG within a cell appears either 
methylated, hemi-methylated or de-methylated and estimations indicate that within the human 
genome there are roughly 28 million CpGs (59).  
The chemical addition and removal of a methyl group to cytosine is performed by several 
different enzymes. DNA methyltransferases (DNMTs) act in the establishment of de novo 
methylation (DNMT3A and DNMT3B) or preservation of the methylation status during cell 
division (DNMT1). DNA methylation within CpG rich promotors of genes is associated with 
transcriptional repression (Fig. 2C/D) (60), while higher methylation in gene bodies positively 
correlates with expression, likely due to blocking the binding sites of alternative promotors and 
altering the kinetics of transcription. Furthermore, studies suggest that methylation can also 
influence splice variants.  
Meanwhile, in addition to passive mechanisms, DNA de-methylation can occur by the ten-
eleven translocation family of proteins (TETs), which oxidize 5mC to 5-hydroxymethyl 
cytosine (5hmC), followed by further downstream metabolization. 5hmC has been 
demonstrated to be stable and to functionally regulate the genome with higher abundance in 
certain tissues such as lungs, testes and CNS [41]. Higher levels of 5hmC in the body of genes 
correlate positively with transcription. The role of DNA methylation is highly complex and 




Figure 2. Chromosomal organization and DNA methylation. A) The organization of a chromosome, 
with the chromatin, nucleosome, with histone modifications, down to the DNA sequence where the 
chemical modification of cytosine takes place. B) The different bases with the different methyl groups 
attached. C) An unmethylated promoter with methylated gene body CpGs that results in expression. 
D) A methylated promoter of a gene that is not expressed. 
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5.2 EPIGENETIC METHODS 
The methyl group can be distinguished either by methylation-sensitive enzymes or by 
chemical treatments such as bisulfite conversion, which chemically alters un-methylated 
cytosines to uracil, further amplified to thymine, with the ratio of C / T in the post-bisulfite 
downstream analysis representing the methylation level. Here it is important to realize that 
the level of methylation in a single cell is usually binary, but samples represent a mixture of 
many cells. Therefore this methylation measurement represents the average of the cells 
measured, and this also means that the difference in methylation levels found might represent 
a difference between cell mixtures.  
Current high-throughput methods allow for genome-wide profiling of DNA methylation with 
a relatively small amount of DNA required. As a result, high throughput methods are well 
suited for clinical studies where MS immune or CNS cells are compared with healthy controls 
to identify differentially methylated positions (DMPs) and regions (DMRs). The most 
commonly used genome-wide methods include microarray approaches such as Illumina 
450K (450K) and Illumina EPIC (EPIC). Common sequencing-based methods, including 
whole-genome bisulfite sequencing (WGBS) and reduced representation bisulfite sequencing 
(RRBS). Other available techniques include enrichment approaches like the Agilent 
Sureselect Methyl-seq or immunoprecipitation approaches such as methyl-CpG sequencing 
(meDIP-seq) or methyl-CpG binding domain sequencing (MBD-seq). Locus specific 
techniques include pyrosequencing, qPCR and methylation-specific PCR. 
The ratio of C / T following bisulfite treatment in methylation data is calculated for every 
CpG as a beta (β) using the following formula: 
𝐵𝑒𝑡𝑎𝑖 =  
𝑚𝑎𝑥(𝑌𝑖, 𝑚𝑒𝑡ℎ𝑦, 0)
𝑚𝑎𝑥(𝑌𝑖, 𝑢𝑛𝑚𝑒𝑡ℎ𝑦, 0) +  𝑚𝑎𝑥(𝑌𝑖, 𝑚𝑒𝑡ℎ𝑦, 0) +  𝛼
 
 
This beta can be transformed in to log2 space as a M value, which is calculated as: 
𝑀𝑖 = 𝐿𝑜𝑔2 (
𝑚𝑎𝑥(𝑌𝑖, 𝑚𝑒𝑡ℎ𝑦, 0) +  𝛼
𝑚𝑎𝑥(𝑌𝑖, 𝑢𝑛𝑚𝑒𝑡ℎ𝑦, 0) +  𝛼




where 𝑌𝑖 , 𝑚𝑒𝑡ℎ𝑦 and 𝑌𝑖, 𝑢𝑛𝑚𝑒𝑡ℎ𝑦 are the intensities measured by the i
th methylated and 
unmethylated probes (61). In the formula, the α is a constant offset added to the intensity 
value of methylation arrays to regularize the beta value when intensities are low. While the 
beta value is attractive due to the direct biological interpretation, it has a bounded range, and 
this creates problems with the assumption of a Gaussian distribution of many statistical tests, 
on the other hand, M value is more statistically valid in differential analysis. However, the 
M value is more challenging for biological interpretation.  
5.3 ANALYSIS PIPELINES 
The platform of choice for most human studies used the 450K array while recent ones have 
updated to the EPIC array. Illumina arrays are used due to the low costs and low amount of 
input DNA required. The array design started in 2008 with the Illumina 27K which had 
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~27 000 probes with a type I probe chemistry. This was followed up in 2011 with the 450K 
array, which has ~480 000 probes, covering ~99% of all refseq genes and was mostly focused 
on CpG islands. Due to the large number of additional probes required, the additional probes 
were designed with new chemistry for specific for type II probes. In 2016 Illumina released 
the Illumina EPIC array, which removed ~50 000 probes from the 450K design due to the 
proximity to SNPs, while the EPIC array has ~400 000 additional probes. These additional 
probes are designed to mostly cover enhancers regions, as identified by FANTOM5 (62). We 
recently demonstrated that the EPIC array could also be used in mice, with over 19 000 
probes mapping to the mouse genome (63).  
As mentioned above, there are two types of probe chemistry in the Illumina design, the type 
I probe design has one bead for the methylated state and another for the unmethylated state 
(Fig. 3). The type II probe design has a single bead, which determines the methylation state 
by using fluorophore coupled single base extension after hybridization (64). The methylation 
levels are then measured using red and green fluorescence. The type II probes have a higher 
variance, less accuracy and are less sensitive to extreme methylation signals (65). Due to this, 
several specialized normalization pipelines have been established using peak-based 
correction. A commonly used pipeline includes quantile normalization, followed by beta 
mixture in-quantile normalization (BMIQ) (66). The remaining batch effects, such as slide 
or position on the slide, can be identified with a data reduction method such as principal 
component analysis (PCA). The identified effects should then be corrected for using batch 
correction tools such as combat (67).  
While running a differential analysis, we aim to compute p-value to address the statistical 
significance of the differences. When comparing, for example, MS cases with healthy 
individuals to identify statistically significant differences, several potential independent 
variables have to be considered and controlled for. These covariates are elements that can 
affect the methylation level that could increase the heterogeneity of the clinical signal. These 
can include age, gender, and treatment history, among others, but this depends on the exact 
statistical question and cohort design and the power to detect interactions. A proper way to 
statistically control for this is to set up a linear model to regress out the effect of the covariate 
so that only the dependent variable remains.  
The output of a statistical test is a p-value, and the p-value represents the probability of a type 
1 error, a false rejection of the null hypothesis, meaning that there is no difference between 
the groups tested. Therefore, if the p-value is smaller than 0.05 than there is a less than 1 in 
20 probability that the null hypothesis is true, meaning there is a high probability that it needs 
to be rejected because there is a difference between the tested groups. Usually, the 
significance cutoff is set for 0.05, however, if we preform 450 000 tests on the 450K array, 
this would mean that there could be up to 22 500 type 1 errors if there is no adjustment for 
multiple tests. Adjusting for multiple testing refers to the re-calculating of the probabilities 
obtained for the number of times the test was performed. There are several methods for this, 
but the common methods include Bejamini Hochberg for False-Discovery Rate or Bonferroni 
for Family Wise Error rate correction (68). We usually select CpG sites with an adjusted p-




Figure 3. Illumina methylation array probe design (64). Blue is a single bead, the red box is the 
CpG locus and the orange line is the bisulfite converted DNA. A) The design of the Illumina EPIC 
slide. B) The design of the type I probes, which has one bead for the methylated strand and a 
separate bead for an unmethylated strand. C) The design of the type II probes, where there are both 
methylated and unmethylated signals on the same bead. 
 
6 EPIGENETIC STUDIES IN MS 
6.1 IMMUNE CELL STUDIES 
The first genome-wide DNA methylation study in MS from Baranzini et al. used RRBS 
covering > 1.7 million CpGs in CD4+ T cells of three MS-discordant MZ twin pairs (69). The 
study found very few DMPs but these had large variations within twin pairs, none of which 
passed genome-wide significance or were shared between the pairs. However, due to small 
sample size, heterogeneity of the individuals, and low genome coverage of their sequencing 
data, as well as their focus on large differences, several important sites may have been missed. 
Handel et al. (70) investigated the role of DNA methylation of the HLA-DRB5 and HLA-
DRB1 locus in peripheral blood mononuclear cells (PBMCs). They compared patients 
classified as either benign or malignant based on EDSS, but none of the CpGs investigated 
showed any significant effects between the two groups. There was a non-significant trend 
towards more HLA-DRB5 DNA methylation in the malignant than the benign group.  
Graves et al (71) used Illumina 450K to analyze CD4+ T cells from 30 RRMS patients and 
compared them to 28 healthy controls. Notably, contrary to Handel et al. (70) the authors 
found strong methylation differences in the HLA locus and especially the HLA-DRB1 gene. 
In CD4+ T cells the HLA-DRB1 locus displayed strong hypomethylation, and in addition, 55 
non-HLA differences were reported. Interestingly, a large portion (54%) of the non-HLA 
differences map to genes that have previously been reported in the context of MS. In the 
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follow-up study in CD8+ cells from the same cohort, Maltby et al. (72) could not confirm the 
changes in HLA-DRB1, and none of the CD8+ differences mapped to MS reported genes. 
Only one gene overlapped between the studies, the MORN1 gene but with different CpGs in 
the two studies, indicating different epigenetic MS signatures between CD4+ and CD8+ T 
cells. Maltby et al. also studied CD19+ cells and found a larger number of DMPs compared 
to CD4+ cells or CD8+ cells (73), with over 7000 sites having a nominal p-value < 0.05 and 
Δβ > 0.1. They found a large DMR in the LTA gene, which encodes the Lymphotoxin-alpha 
(LT-α) protein. LT-α is a TNF family member produced by lymphocytes that promotes 
lymphocyte proliferation and immune activation via NF-κB (74). Increased LT-α has been 
implicated in MS before (75). Other reported genes belong to the NF-κB cascade, as well as 
IL21R, a receptor involved in B cell proliferation (76). 
Bos et al. (77) analyzed CD4+ and CD8+ T cells sorted from peripheral blood, as well as 
matching whole blood of MS patients and healthy controls using the Illumina 450K array. 
This study also highlighted the importance of separating different immune cell 
subpopulations in DNA methylation studies, with only a few overlapping CpGs between the 
cell types. The biggest differences were seen in the TMEM48 transcription start site (TSS), a 
gene involved in a nuclear pore complex. Nominally significant CpGs in the first exon of 
APC2 were found, a gene involved in microtubule and beta-catenin binding. Additionally, 
the DNHD1, also involved in microtubule movement, displayed several CpGs throughout the 
gene. Interestingly, this study revealed a strong hypomethylation of CD8+ cells in patients 
with duration over 7 years or lower, compared to those with a duration above 8 years. Rhead 
et al. (78) combined the data from Bos et al. with those of Maltby et al. and saw significant 
differential methylation in 4 different loci, namely those in the MOG/ZFP57, HLA-DRB1, 
NINJ2/LOC100049716, and SLFN12 genes.  
Neven et al. (79) investigated methylation of the Alu, LINE-1 and SAT-α, which are known 
as estimators of global DNA methylation levels, and together form around 33-35% of the 
entire genome. In total, 51 MS patients and 137 matched healthy controls were compared and 
showed significant hypermethylation of these repetitive elements. Lower levels of Line-1 
methylation was associated with a lower EDSS while higher levels of Alu methylation 
associated with a lower EDSS. 
Kulakova et al. (80) investigated DNA methylation using 450K in PBMCs from 14 RRMS 
and 8 PPMS patients compared with 8 healthy controls. More than half of the differential 
CpGs found had higher levels of methylation found in RRMS and PPMS when compared 
with controls, but PPMS genes also had higher levels of methylation than RRMS. 
Interestingly the ESRRG gene, a potential transcription factor for DMNT1, was found 
differentially methylated in RRMS. PPMS which is thought not to have a sizeable immune 
component, still had differential methylation of the immunological genes HLA-F, MTPN, 
VIPR2 as well as autophagy gene ATG16L2. These data indicate that the methylation profiles 
of PBMCs from PPMS are distinctly different from that of RRMS.  
Souren et al. looked in PBMCs from 45 monozygotic twin pairs discordant for MS using the 
EPIC array (81). After adjusting for cell-type composition, no genome-wide significant 
changes were detected, but the top genes included ZBTB16, TMEM232, SEMA3C, YWHAG, 
and MRI1. Epigenetic changes in ZBTB16 and TMEM232 were validated in a cohort of four 
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CD4+ samples analyzed with WGBS. ZBTB16 is a GC response gene, which is not covered 
by the 450K array and while the TMEM232 gene had a large DMR the function of this 
transmembrane gene is currently not known. In the CD4+ cohort, they also identified a 
prominent DMR in the intronic CTCF/YY1 bound regulatory region in FIRRE. In the specific 
setup of this study, they could also identify a signature associated with interferon (IFN) 
treatment, one of the most commonly used MS modifying treatments. The IFN analysis 
showed 212 genes associated with the top DMP located in the RSAD2, MX1, IFI44L and 
PLSCR1 genes, which are reported to be higher expressed in the blood cells of IFN-treated 
MS patients. 
The strongest genetic risk factor in MS is the HLA-DRB1*15:01 haplotype, which confers a 
3-fold increase in MS risk and in the paper of Kular et al. we investigated the role of DNA 
methylation in the HLA-DRB1*15:01 gene (82). In the analysis of MS compared with 
healthy controls in CD14+ monocytes we identified a DMR in exon 2 of the HLA-DRB1 
gene, where HLA-DRB1*15:01 carriers had lower methylation and a higher expression of 
the HLA-DRB1 gene. We used causal inference testing to establish a causal link between 
genetic background, DNA methylation levels and HLA-DRB1 expression. Causal inference 
testing identified seven DMRs that could mediate the genetic risk, six of which we could 
confirm using CD4+ T cells, CD8+ T cells and CD19+ B cells. We further used two-sample 
Mendelian randomization to determine the causal link between genetic variation in the HLA-
DRB1 gene, its methylation and expression levels. This is the first study in MS demonstrating 
that DNA methylation can mediate the risk of developing the disease. 
Few studies up to date investigated changes in the epigenome after treatment in MS patients. 
MS treatment is centered on the dampening of the immune response and reducing the 
inflammation in the CNS. DMF has several functions which are still being investigated, but 
a central effect is that it releases nuclear factor erythoid 2-related factor 2 (NRF2) from 
KEAP1 and results in the upregulation of ROS related genes and influences the polarization 
of T cell subtypes (83). Matlby et al. looked for the changes in CD4+ T cells between baseline 
and 6 months of treating with DMF, and identified four genes, SNORD1A, SHTN1, MZB1 
and TNF (84). Ntranos et al. compared DMF treated patients with both glatiramer acetate 
patients as well as treatment naïve patients (85). Here they found hypermethylation of MIR21 
locus in CD4+ T cells from the DMF treated patients. They also show that the 
hypermethylation of MIR21 also occurs in cells in vitro in a dose-dependent manner. 
6.2 EPIGENETIC INTERACTION WITH ENVIRONMENT 
Several studies have looked at the influence of the environment on the epigenome in the 
context of MS.  
One of the top environmental risk factors is smoking. Smoking is a risk factor that has been 
associated with many diseases, and in MS it is associated not only with an increased risk of 
developing MS [32], but also with faster progression and clinical disability [33]. The odd 
ratios of several genetic risk factors increase significantly due to the interaction with smoking 
(86). Studies in the Nordic countries, such as Sweden, where oral tobacco is popular suggest 
that this effect might be independent of the nicotine and might be due to immune activation 
in the lungs. Marabita et al. investigated the effect of smoking on PBMC DNA methylation 
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in MS patients (87). Notably, although smoking in MS induced methylation changes on the 
same CpGs as in healthy individuals, the amount of smoking had significantly more 
pronounced impact on methylation changes in MS patients, as demonstrated, e.g. a CpG in 
the AHRR gene, among others. This implicates interaction between smoking and disease 
processes in impacting the epigenome. Interesting is that the Ahr pathway, where AHRR 
belongs to, is a known regulator of Th17 and Treg subsets (88).  
Vitamin D, which has a strong associated with MS (89), is activated in the skin under exposure 
of UV from sunlight and has a protective role via dampening inflammatory actions of APCs, 
T and B cells. Vitamin D receptor (VDR) is a nuclear receptor, whose binding sites in 
lymphoblastoid cell lines are enriched near loci that associate with autoimmune diseases and 
with genes, which are differentially expressed between MS and controls (90). In EAE vitamin 
D supplements can dampen the severity of disease due to reduced proliferation of CD4+ T cells 
(91). Using MBD-seq and ChARM arrays, it was demonstrated that vitamin D-
supplementation in rats results in hypomethylation in CD4+ cells and their reduced activation 
state and pro-inflammatory phenotype.  
Previous studies have indicated that a risk factor for MS is a high BMI in early life. Castro et 
al. investigated the effect of BMI on the epigenome of peripheral monocytes (92). High BMI 
MS patients had hypermethylation of several genes, including NRXN1, TP63 and FZD7, 
which indicates a negative regulation of anti-proliferative genes. Using lipidomic profiling 
of plasma samples identified the presence of increased ceramide species in MS patients with 
high BMI. Ceramide species are a precursor to sphingosine-1-phosphate, whose receptor is 
the target of fingolimod (50) and siponimod (51). Similar DNA hypermethylation changes in 
these genes could be detected after ceramide treatment in cell cultures, but only if the 
ceramide concentration was similar to those high BMI MS patients. Furthermore, a high BMI 
correlates with an increase in monocytes and a decrease in brain volume of MS patients.  
A contribution of EBV to MS has been debated for a long time, as nearly all MS patients are 
EBV positive compared to 90-95% of the general population (93), though the odds ratio for 
developing MS increases significantly if the patient has a history of infectious mononucleosis 
(94). Furthermore, EBV infects memory B cells in the CNS (43). Interestingly, the EBV viral 
load is modulated by HLA alleles, with an increased presentation with HLA-DRB1*1501 and 
lower load with HLA-A*02, which matches with HLA-DRB1*1501 being a negative risk 
factor, while HLA-A*02 has a protective effect (95). Ong et al. studied EBV transformation 
of lymphoblastoid cells lines (LCLs) to investigate the interaction between EBV infection 
and MS (96). They saw that despite that EBV transformation results in predominantly 
hypomethylation, the regions around the MS risk loci were less likely to be hypomethylated 
than randomly selected regions, though they argue that this could be in part due to the 
constitutive B cell utilization of these regions.  
Several studies have tried to use DNA methylation to set up a clock that aims to capture the 
biological age of a tissue rather than the chronological age (97, 98). Theodoropoulou et al. 
looked at the effect of epigenetic aging as measured by DNA methylation in MS and found 
that epigenetic age is different between men and woman for different cell types (99). While 
the Age Acceleration Residual indicated a decelerated aging in MS woman, likely due to 
differences in cell frequencies, the Phenotypic Age Residual indicated accelerated 
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phenotypic aging in MS patients. Age is an important covariate in many diseases and in MS 
the risk for progression triples after the age of 50 (100). The potential for increased risk of 
progression after the age of 50 could be due to the accelerated aging of the immune system 
(inflamaging) caused by long-term chronic inflammation (101).  
6.3 CNS STUDIES 
Neurological diseases such as MS are challenging to study in a clinical setting due to the limited 
accessibility of the CNS. Nonetheless, several studies have investigated epigenetic changes of 
the CNS tissue from MS patients. The first study to do so by Mastronardi et al (102) studied 
citrullination of myelin basic protein (MBP), a major constituent of myelin in the CNS, which 
can display differential post-translational modifications. Citrulination of MBP by the peptidyl 
arginine deaminase 2 (PAD2) gene is increased in Normal Appearing White Matter (NAWM) 
of MS patients, and this is thought to contribute to loss of immune tolerance. In NAWM 
biopsies from MS patients, the PAD2 promoter was hypomethylated, and this effect appears to 
be MS specific with no differences seen in the thymus gland or in white matter from other 
neurological diseases. The PAD2 expression and promotor hypomethylation effect were also 
seen in PBMCs of MS patients by Calabrese et al. (103) though the role of PAD2 in PBMCs 
still has to be determined. 
Huynh et al. (104) used 450K to investigate at genome-wide DNA methylation changes in 
pathology-free NAWM brain regions from MS patients compared to unaffected controls. In 
a cohort of 23 MS patients and 19 healthy controls, they found 539 significant DMRs in MS 
brains compared to controls, and the DMRs were preferentially found in genomic locations 
associated with enhancers. DNA was found to be hypomethylated at the TSS but was 
hypermethylated in gene body CpGs. Hypermethylated and lower expressed genes include 
MBP, SOX8, a gene associated with sex determination (105), NDRG1, a gene involved in 
oligodendrocyte response to stress and BLCL2, an anti-apoptotic BCL2 family member. 
Meanwhile, proteolytic processing related genes LGMN and CTSZ were hypomethylated and 
expressed at higher levels. An important note is that the used methodology cannot distinguish 
between 5mC and 5hmC, enriched in neurons, which might contribute to some of the 
differences seen in the NAWM. Nevertheless, this study still highlights the numerous 
epigenetic changes in the CNS of MS patients influencing its homeostasis and its ability to 
repair itself after damage. 
We recently published a paper where we studied DNA methylation of neurons from post-
mortem brain tissue from MS patients and non-disease controls (106). Due to the high 
proportion of 5hmC in neurons, we investigated both 5hmC and 5mC. We also deconvoluted 
for glutamate and GABA neuronal fractions, the two main types of neurons. Interestingly, MS 
neurons were characterized by a sustained hypo-5mC and hyper-5hmC methylation, clustering 
mainly in gene bodies and associating with decreased gene expression. Altered genes belong 
to processes involved in synaptic plasticity, axonal guidance and CREB signaling pathway. We 
identified a reduction of CREB activity in MS samples, which could be confirmed with 
immunofluorescence of brain slides.  
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6.4 OTHER EPIGENETIC REGULATION 
There are abundant well-established methods to study DNA methylation, but 5mC is far from 
being the only level of epigenetic regulation. In the nucleus, the negatively charged DNA is 
tightly wrapped around a positively charged octamer complex of four dimer proteins called 
histones (Fig.2 A), and together they form a structure called a nucleosome, which controls the 
accessibility of the chromatin. The tails of the histones or the specific histones variants 
themselves can undergo changes, which can affect how accessible genetic loci are to the 
transcriptional machinery. This N-terminal tail can undergo a multitude of simultaneous post-
translational modifications (PTM). The acetylation of histone H3 is associated with 
transcriptional activation and is acetylated by histone acetyltransferases (HATs) and HDACs. 
HDACs are not only blocked by the MS drug fingolimod, but it has also been demonstrated 
that EAE can be treated by the use of HDAC inhibitors (107, 108). Furthermore, SNPs in genes 
encoding HDACs have been suggested to predict brain volume in MS patients (109). Recent 
work by Roy et al. demonstrated that the methionine is absorbed by CD4+ T cells, which serves 
as a donor for S-adenosyl-L-methionine (SAM) (110). Restriction of methionine in the diet of 
mice reduced H3K4 methylation in Th17 genes, and they demonstrate that restriction of 
methionine alters the expansion of pathogenic Th17 cells, which subsequently reduces EAE 
severity.  
Another regulatory level sometimes included in the term epigenetics comprises non-coding 
RNAs, which can include long non-coding RNAs (lncRNA), some of which have shown to be 
deregulated in the serum of RRMS patients (111), as well as small non-coding RNAs 
(sncRNA). Among the most studied sncRNAs are microRNAs (miRNA). MiRNA are 
transcribed in the nucleus where they form a hairpin structure, which is transported to the 
cytosol, where Dicer cleaves it into single-stranded RNA. The 3p or the 5p strand are then 
incorporated together with the Argonaute (Ago) protein into a RISC complex. They are 20-25 
bp long RNAs which use a 6-8 base seed sequence to identify and bind target mRNAs, with 
one miRNA being able to target several mRNAs, and control protein levels within the cell and 
tissues (112). MiRNA act intracellularly but can also be found in extracellular biofluids, such 
as plasma and CSF.  
They are currently intensively investigated for their biomarker potential, e.g. miR-150 is 
increased in the CSF of MS patients and correlates with more active disease and clinical 
parameters such as CSF cell count, immunoglobulin G index, and presence of oligo clonal 
bands (113). As of 2019, the role of miRNA in MS has been studied in over 61 studies with 
over 500 miRNAs reported as dysregulated. Piket et al. reviewed these studies (114), and the 
results indicated that the top miRNA-affected pathways in MS are linked to TGF-β-, B cell 
receptor-, PTEN-, MERK/MAPK-, PI3/AKT- and NF-κB signaling. Furthermore, the data 
indicated that the circulating miRNAs have a promising potential as MS biomarkers. However, 
the data also demonstrated noticeable inconsistencies among the results, which could be due to 







A growing body of evidence suggests that epigenetics plays a role in the development and 
progression of MS but finding changes and markers, which are validated, has been a major 
issue. Several different studies have been performed, as described above, yet the studies have 
widely different results with minimal overlap. The disparity between the studies might have 
resulted from several different issues. The epigenetic marks found in different tissues and cell 
types are going to be highly diverse, and the potential low power of the study in question, the 
genetic variation, environmental factors as well as or on-going disease processes or therapy 
will further influence the different results.  
7.1 COMPARING AMONG STUDIES 
A large problem in comparing cohorts is the statistical analysis used to find differences, with 
every study using different pre-processing and normalization techniques for the data analysis, 
and, while the pipeline outlined above is common, several studies use different approaches. 
For instance, Graves et al. used a two-sided Kolmogorov–Smirnov (KS) test to find differences 
(71), which accompanied by a step-wise filtration process to remove probes associated with 
either gender or treatment in a subgroup of patients. Most of the other studies use a linear model 
that includes age and sex as covariates. Some studies use cell type deconvolution to remove 
the effects of different cell mixtures (115), but other studies do not. Furthermore, some studies 
with low power to detect changes do not reach statistical significance; therefore, they use a 
different cutoff to report results. The use of different linear models with corrections for different 
covariates and different statistical cutoffs for calling significant results poses difficulties with 
comparing the outcomes of different studies.  
7.2 INTEGRATING STUDIES 
An approach to integrate the efforts conducted in the different studies is to use meta-analysis 
(116), which combines the evidence from different independent studies. There are several ways 
to compare the evidence from different studies, either their p-value or the effects of the findings. 
A combination of the p-values can be done using several different methods, but a common one 
is to use the Fisher's combined probability test. An effects based meta-analysis can be 
conducted using either a fixed-effects or a random-effects model. A Fixed effect model 
considers that the effect of the covariates in the studies are comparable across all populations, 
while a random-effects means that the effect of covariates can vary between populations. As a 
result, if it possible to accept the assumptions, the fixed-effect model provides higher statistical 
power; however, considerable heterogeneity between studies, meaning inconsistent patterns 
between the compared cohorts, often requires the use of a random-effects model.  
7.3 META-ANALYSIS OVER PAIRED DATA OMICS DATA 
A recent addition to the meta-analysis toolbox comprises a method called OmicsNPC from the 
STATegra R package (117). This tool uses information from multiple omics layers and utilizes 
both permutations and non-parametric combinations to combine data with minimal 
assumptions. These layers could be paired data from several different cell types or the same 
samples analyzed with different technologies. The permutations are used to normalize between 
cohorts, making all the distributions on the same scale. When using the same samples in 
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multiple groups, it is essential to preserve local correlation by permuting the same way across 
all modalities. After permutations, a permuted p-value is generated based on the ranking of the 
statistic of interest with the permuted statistics. The permuted p-values are combined using one 
of several different non-parametric combination methods: Tippett, Fisher or Liptak. Each has 
its own specific assumptions and different rejections of the null hypothesis.  
 
Figure 4. The different rejection limits of the different OmicsNPC tests. The green line indicates that if 
one of the Liptak p-value is too large, it will be rejected. Remade with permission from the original 
authors(117) 
An interesting property of the Stouffer-Liptak method, Tl= ∑ ϕ
-1(1-λb
i ), is that there has to be 
minimal evidence for rejecting the null hypothesis in all studied combinations, or the test result 
would not be significant (Fig. 4). Practically, this means that if the studied change/gene is 
significant in all cohorts or modalities, it will be significant using the Stouffer-Liptak test. 
However, if the studied change/gene were not significant in one of the cohorts or modalities, 
then the null hypothesis would not be rejected even with overwhelming evidence from the other 
studied cohorts or modalities.  
7.4 FUNCTIONAL RELEVANCE 
Moreover, the functional relevance and causality of epigenetic changes need to be considered. 
Not only which genomic loci contain differences but also how sizeable are these differences, 
as MS typically exerts small changes in DNA methylation. The direction of the change can 
also mean different things depending on the affected genomic feature, e.g. promoter 
methylation correlates with transcriptional repression, gene body methylation correlates with 
transcriptional activity while methylation around splice sites can influence splice variants 
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(118). There is the question of whether studies should focus on DMPs or DMRs, as changes in 
DNA methylation are often correlated between the neighbouring CpGs, however here 
technology might limit what we can detect. The cross-talk with other regulatory mechanisms 
should also be taken into consideration when assessing the functional relevance, such as genetic 
background, histone modifications, ncRNAs and transcription. Because of potential variation 
in all these levels, it is challenging to assess the functional consequences of changes without 
proper in vitro or in vivo reporter systems.  
To assess the functionality of the differences found, current studies use the closest gene as an 
identifier of functions. The Illumina arrays have a manifest which maps every CpG to a specific 
gene. While several CpGs are mapped to several genes, usually for interpretative purposes the 
closest is used. This could lead to problems where the gene affected by the differential 
epigenetic marks is not used in functional analysis. These genes are then typically used for gene 
set enrichment or pathway analysis tools, such as Ingenuity Pathway Analysis (IPA) (119), 
GREAT (120), GSEA (121), among others. These tools make use of curated collections of 
gene-sets such as Gene Ontology (122) or KEGG (123) to identify those relevant (statistically 
significant) gene-sets associated with the trait of interest. However, GSA outcomes may 
become challenging to interpret when the number of gene-sets identified is very large or if the 
results from different collections of gene-sets, i.e. different experiments, are combined. An 
additional challenge appears when identified gene-sets have a high gene content overlap, which 







8 THESIS AIMS 
 
The overall aim of this thesis was to characterize the changes in DNA methylation in immune 
cells from MS patients during disease development, disease progression and treatment, and 
from them to infer functional pathways of importance for MS pathogenesis: 
 
Study I 
To investigate DNA methylation patterns across four different peripheral immune cell types 
during the development and progression of MS. 
 
Study II  
To investigate changes in DNA methylation between MS cases and controls and characterize 
the role of DNA methylation in the dysregulation of miR-21 in CD4+ T cells in RRMS patients. 
 
Study III 
To develop an R tool which offers a simple approach to gain biological insights from one or 
more gene-set analysis results or tools. 
 
Study IV 
To utilize epigenetic marks in peripheral immune cells following DMF treatment in RRMS 
patients to gain insights into the mechanisms of the treatment. 
 
Study V 
To characterize in depth the changes in DNA methylation of peripheral CD19+ B cells between 
RRMS patients and healthy controls, as well as to investigate the effects B cell depletion on 





9.1 STUDY I 
In this study, we profiled DNA-methylation of four different peripheral immune cells (CD4+ 
and CD8+ T cells, CD14+ monocytes and CD19+ B cells) in RRMS and SPMS and matched 
healthy controls (HC) using the Illumina 450K array. The RRMS patients constituted of a 
mixture of newly diagnosed patients, and patients who were on a drug washout for a period of 
around 6 months, all who had non-active disease as confirmed with MRI. From every patient, 
we sorted all four immune cells, though due to the quality and quantity of the DNA, not every 
cell type was analyzed for every patient.  
Differential methylation analysis detected 30, 666 and 1 511 significant DMPs in CD8+, CD14+ 
and CD19+ samples between RRMS, SPMS and HC in a linear model that included age and 
sex as covariates. Because of the high overlap of the results between the different cell types, 
and in order to increase the detection power, we combined the evidence of the multiple cell 
types in a non-parametric way using OmicsNPC. We developed a permutation scheme that 
retained the local correlation between cell types and ran the pipeline with 10 000 permutations. 
This resulted in 1976 DMPs from all four cell types (Fig 4). We confirmed the shared nature 
of the probes by testing the direction change in HC vs RRMS, and RRMS vs SPMS and saw 
that the direction was shared more often than expected by chance, as well as a very high 
correlation of the t statistic between the different comparison for the 1976 shared probes. The 
additional discovery power was confirmed in a small independent cohort of HC and RRMS 
samples from CD14+ samples run on the Illumina EPIC array. Furthermore, we saw an 
enrichment of the shared DMPs in MS susceptibility loci as identified by the latest MS GWAS. 
 
Figure 5. Overview of the omicsNPC function used in study 1. (124) A) Overview of the omicsNPC 
pipeline. Data was permuted 10,000 times using random labels that were consistent between individuals 
with the different cell types to maintain the correlation between the cell types. The permuted p-values 
were combined using the Liptak-Stouffer test, and the Liptak score was used for determining the shared 




Next, we clustered the shared DMPs into changes that were either specific for the MS samples 
in general (RRMS and SPMS), changes that were specific for SPMS samples or changes with 
no clear pattern between the samples or the different cell types. The functional annotation of 
the MS cluster implicated lymphocyte signaling, T cell activation and migration. The SPMS 
cluster implicated myeloid cell functions and metabolism, as well as an interesting signature 
coming from neurodegenerative genes, which we could confirm in a whole blood cohort of MS 
samples. In conclusion, OmicsNPC allowed for the detection of changes between cases and 
controls despite limited power of the study. Our findings provide new insights into the 
molecular mechanisms underlying MS pathogenesis and particularly disease progression. 
9.2 STUDY II 
In this study, we investigated the functional changes of the top DMP found in the CD4+ analysis 
of the DNA methylation data from study I. In CD4+ T cells, we did not identify genome-wide 
significant DNA methylation changes; however, among the top most significant hits we 
identified a DMR in the MIR21/VMP1 locus, where RRMS samples had higher methylation 




Figure 6. Overview of the DNA methylation changes surrounding the VMP1/MIR21 locus. (125) 
We replicated the findings using a meta-analysis between our data and that of the independent 
cohorts from Bos et al. (77) and Graves et al. (71). Here both a p-value based and an effects-
based meta-analysis confirmed the higher methylation in RRMS. Using the CD4+ T cell 
methylation data from the GOLDN cohort (126), we excluded a substantial effect of a genetic 
variation in this locus, known to be one of the MS risk loci, on DNA methylation only. The 
GOLDN data also confirmed that there was no effect of smoking on MIR21/VMP1 DNA 
methylation, while DNA methylation levels did correlate with lymphocyte count and age. 
Using qPCR, we confirmed that the DMR only had an effect on miR21 levels but not on VMP1, 
with lower expression levels of miR21 in RRMS patients, which we could validate in an 
independent cohort. Using the data from the RNA sequencing of the same samples used for 
DNA methylation (127) we could confirm the higher expression of miR21 target genes. Thus, 
our findings suggest epigenetic silencing of mir-21 in CD4+ T cells, leading to a reduced miR-
21 mediated silencing of target mRNAs. 
9.3 STUDY III 
In this study, we further developed the tool used in studies I, IV and V. GeneSetCluser is an R 
package we developed to help in understanding the results from pathway analysis. When we 
ran IPA on the genes mapped to the DMPs from the OmicsNPC analysis, we struggled to 
interpret the results due to the same genes appearing repeatedly enriched in the multiple 
significant gene-sets. To aid in the interpretation, we used the overlap of genes in order to 
calculate a distance score between the different gene-sets to cluster them into more easily 
interpretable clusters. After the usefulness of this methodology in studies I and IV, we further 
developed this into an R-package which we called GeneSetCluster. GeneSetCluster can be used 
to cluster together data from a single gene set enrichment run as well as multiple experiments 
and conditions. The package was designed to be able to use information from all databases and 
tools and can convert between gene ID from multiple sources and species. Data can be 
visualized using a heatmap, an example of how these results look from study IV can be seen in 
figure 7B, and networks and can aid in the interpretation of gene-set enrichment results. Our 
method is currently available in an R-package from GitHub 
(https://github.com/TranslationalBioinformaticsUnit/GeneSetCluster). 
9.4 STUDY IV 
In this study, we investigated the molecular effects of DMF treatment on the monocyte 
response and changes in CD4+ T cells. To this end, selected patients, which started DMF 
treatment at the MS clinic of the Karolinska University Hostpital and who met the 2010 
McDonald criteria for RRMS. Patients were characterized at baseline, 3 months and 6 months 
after DMF treatment. 
Nrf2 is a target of DMF but the precise effects remain elusive. We saw that there was an 
increase of intracellular ROS after 3 months, which increased further after 6 months. Changes 
in expression, measured using microarrays, showed enrichment of the GO term: Regulation of 
response to oxidative stress. DNA methylation was measured on the Illumina EPIC array and 
analysis of DMF treatment in CD14+ cells after 3 and 6 months in RRMS patients indicated 
that the methylome changes occur around 3 months but go back to baseline after 6 months. 
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Conversely, the changes in CD4+ T cells do not appear until 6 months after the start of 
treatment.  
When stratifying the patients into DMF responders and non-responders, using 24 months of 
follow-up data, we identified a SNP in the ROS-generating NOX3 gene. This SNP is associated 
with both treatment response and ROS production, interestingly though this gene is not 
significantly associated with the risk of MS. The NOX3 gene displayed different expression 
based on the genotype of the SNP as well as different methylation levels.  
 
Figure 7. Effect of DMF treatment on DNA methylation in CD4+ T cells. Figure adapted from (128) 
The delayed DNA methylation changes in CD4+ T cells around 6 months did coincide with the 
changes of naïve and effector memory T cells in DMF responders, even though the total 
number of T cells was down in DMF responders. The changes in CD4+ T cell subtypes were 
supported by the identified differentially methylated genes, enriched in pathways such as 
HIPPO signaling and T cell differentiation, and the increase of Th17 associated plasma 
cytokines in DMF responders after 6 months. This data implicate monocyte-derived processes 




9.5 STUDY V 
In study I we saw that the majority of DNA methylation changes between RRMS and HC 
occurred in CD19+ B cells. Due to this finding coupled with the increasing interest in the role 
of B cells in MS due to the highly effective B cell depleting drugs such as rituximab, we decided 
to further explore the epigenetic changes in CD19+ B cells. To that end, we analyzed a second 
larger cohort of CD19+ samples, which was collected from all patients treated in the local MS 
clinic. DNA methylation was measured using the Illumina EPIC array, which we compared 
with the results from study 1 using four different meta-analysiss approaches. These included 
two different fixed effects and one random-effects model as well as a combination of both data 
sets where batch effects were removed with ComBat. We identified 3 003 different DMPs with 
a significant adjusted p-value in all four different pipelines. The functional annotation of the 
epigenetic changes in CD19+ B cell indicates alterations of multiple processes in MS. These 
include changes associated to phosphoinositides, glucose and lipid metabolism, as well as 
changes associated with the regulation of cell cycle, apoptosis and differentiation of B cells, 
and changes in cell adhesion. Interestingly, the latter involved changes in multiple molecules, 
typically known as axon guiding genes.  
 
Figure 8. Methylation changes in CD19+ B cells sorted from peripheral blood of relapsing-remitting 
Multiple Sclerosis (RRMS) patients and healthy controls (HC). Cohort 1 (purple), measured using 
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Illumina 450K arrays, Cohort 2 (orange), measured using Illumina EPIC arrays, and Meta (dark green) 
A) Volcano plots illustrate differences in DNA methylation between RRMS and HC. Hyper- and hypo-
methylated CpGs with p-value < 0.001 are indicated in light red and light blue, respectively, while 
darker red and darker blue indicate CpGs with adj. p-value < 0.05. B) Heatmap of the 3 003 probes with 
an adj. p-value < 0.05 (the scale represents Z-score). C) A circular Manhattan plot for Cohort 1 (inner 
circle), Cohort 2 (middle circle) and the meta-analysis (outermost circle).  
In this study, we also investigated the effect of B cell depletion with rituximab on CD4+ T cells 
and CD14+ monocytes in 17 RRMS patients where we measured DNA methylation at baseline 
and after 6 months. The patients had significant depletion of B cells after 6 months, but there 
were no genome-wide significant DMPs in either CD4+ or CD14+ cells. Nonetheless, the top 
hits in both CD4+ and CD14+ were associated with activation of immune cells. Functional 
analysis of the changes in CD4+ cells after rituximab treatment were associated with immune 
activation, and involved in, among other things, Th17 differentiation and IL17 signalling. The 
CD14+ associated changes indicated changes in genes associated with the epigenetic switch 
between pro-inflammatory and anti-inflammatory macrophages as well as monocyte motility 
and activation.  
This data confirm widespread DNA methylation changes in CD19+ cells from RRMS patients 
compared with healthy individuals and inform about the functional consequences that associate 
with MS disease. Accordingly, B cell depletion results in a reduction of activation signals for 





10 CONCLUSIONS AND FUTURE PERSPECTIVES 
In this thesis, we have used several cohorts and methodologies to investigate the role of DNA 
methylation in the development, progression and treatment of MS. We investigated both 
patients with RRMS and SPMS and compared those to healthy controls. We initially looked at 
the four major cell types from PBMC, namely CD4+, CD8+, CD14+ and CD19+ cells, where 
we could identify a DNA methylation signature shared between the different cell types, which 
we investigated more thoroughly using OmicsNPC. Interestingly, using OmicsNPC we 
identified DNA methylation changes in neurodegenerative genes in SPMS patients. In CD4+ 
cells, the top hits indicated changes in the VMP1/MIR21 locus, which we functionally 
investigated and found lower miR21 expression in RRMS patients, which resulted in a higher 
expression of miR21 target genes. Because of the numerous DNA methylation differences 
found in CD19+ cells, we further explored changes in CD19+ cells in a second larger cohort. 
We compared the two different cohorts using several different meta-analysis approaches and 
this resulted in identifying many processes altered in CD19+ cells, including metabolism and 
activation. To analyze the pathway data from the different studies, we developed a method to 
cluster pathways based on the genes inside them, which proved very useful, therefore we have 
further developed this into an R package called GeneSetCluster. 
While epigenetic alteration are stable, they could be affected by changes in the cellular 
environment, so we investigated changes of the epigenome in MS patients after disease-
modifying treatments. The treatment with DMF identified that the changes happen in a cell 
type specific manner, where each cell type has its own specific kinetics. DMF treatment 
resulted in changes in ROS production in monocytes and led to changes in Th17 associated 
genes in CD4+ T cells. Interestingly, we identified a SNP, which associated with ROS 
production and treatment outcome but not with MS susceptibility.  Rituximab treatment, which 
unlike DMF, has an indirect effect on the cells studied, resulted in changes associated with a 
lack of B cell interaction. In CD4+ T cells, we found epigenetic changes in Th1, Th17 and Treg 
associated genes. In CD14+ monocytes, we identified changes in metabolism and motility as 
well as changes in epigenetic genes associated with switching between pro- and anti-
inflammatory macrophages.  
Epigenetic changes, such as the cell type specific DNA methylation changes detected above, 
might provide useful biomarkers for diagnostic, prognostic and therapeutic purposes. The 
reliable quantification of genome-wide DNA methylation levels, which are relatively stable 
and insensitive to handling, make it highly suitable for the clinical setting. For example, 
identification of neurodegenerative signals from in peripheral cells from SPMS patients, offers 
a great potential for insight into diseases, such as MS, where the target tissue is inaccessible. 
The identification of MS associated epigenetic marks will increase in the future when larger 
cohorts are studied with more varied cell types. Furthermore, the rise of new epigenetic 
technologies capable of measuring DNA methylation at a single-cell resolution will allow for 
even more detailed investigation of epigenetically distinct cell mixtures associated with disease 
(129). 
Because changes in epigenetic marks are associated with both disease and treatment, this offers 
promising prospects in correcting dysregulation that can potentially alter the course of MS. 
Besides investigating the epigenetic changes after treatment, changing the epigenetic marks 
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themselves might be a viable strategy for treating MS as well. Epigenetic drugs are classified 
as either, globally altering the epigenome by targeting readers, writers and erasers (HATs, 
HDACs, DMNTs, TETs, etc.) or by altering epigenetic states of specific loci in the genome. 
Global drugs include e.g. the two drugs called azacitidine (AZA, 5-azacitidine) and decitabine 
(DAC, 2’-deoxy-5-azacitidine), which are cytosine analogues that block DMNTs during 
replication leading to demethylation. Two different studies have demonstrated an ameliorating 
effect of these drugs in EAE (130, 131).  
Locus specific methylation changing drugs offer a more exciting approach as they would 
present less adverse effects and more specificity than global drugs. The recently discovered 
ability of CRISPR/dCAS9 to edit the genome in addition to the TALENs and zinc fingers 
proteins offers promising tools to edit the epigenome as well (132, 133). These tools, known 
as EpiEffectors, are fusions of DNA recognition elements fused with catalytic domains of DNA 
methylation related enzymes. The DNA recognition capabilities of guide RNAs (gRNAs) used 
in CRISPR/dCAS9 allow for easy targeting of specific sequences. In contrast, TALENs and 
zinc finger proteins require the design of specific proteins complexes, though CRISPR/dCAS9 
has been noted for its potential number off-target effects, which seem less prevalent using the 
other tools. Current research is investigating the stability of the modified epigenetic marks, as 
well as methods to deliver epigenome-editing tools to target specific tissues and cells (134). 
While more research into epigenome-editing tools is necessary, it is easy to see the potential 
benefits of such technologies. 
The epigenetic studies discussed here, demonstrate changes in epigenetic marks between MS 
patients and healthy controls, however, the interpretation of these epigenetic changes remains 
challenging. More investigations are required to gain a functional understanding of the dynamic 
chromatin changes, so that the causal link between genetic background and environment in the 
context of MS can be understood. Such studies will lead to a better understanding of risk factors 
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